SUN PHARMA GETS BOOST WITH US FDA APPROVAL FOR GLEEVEC

New Delhi: India’s largest drug maker Sun Pharmaceutical announced it received approval from the US FDA for generic copies of Gleevec, a drug that treats chronic myeloid leukemia, a rare form of blood cancer. Sun said it is permitted to launch its versions of Gleevec on Feb. 1, 2016.

At 11.20, (Friday) Sun PharmaBSE 4.02 % stock jumped 4% to Rs. 756 on news of the approval. Gleevec, whose active ingredient is imatinib mesylate, is patented by NovartisBSE -3.51 % and has annual sales of $2.5 billion in the US. Sun said one of its subsidiaries received the final approval for 100 mg and 400 mg tablets.

Over earnings calls Sun Pharma management had informed analysts that it shifted its Gleevec product filings from Halol, a manufacturing site that is presently undergoing corrective actions on directions from the US FDA. Sun had warned it will see a drop in its sales and profit during the year, impacted by issues at its Key Halol site.

Experts said Sun may get a windfall sales of around $250 million during its 6-month exclusivity period. “We have $250 million sales booked for Sun Pharma in our model on basis of 50% market share and 60% price erosion for 6 months. WE assume Sandoz to launch AG in our base case assumption,” said HSBC Girish Bakhru in his note to clients. Recommending a “Buy” on the Sun Pharma stock, Bakhru said Sandoz may launch the authorized generic versions. A few other Indian drug makers including Dr Reddy’s is expected to launch the drug a few quarters after Sun Pharma.

  • Related Posts

    Lupin launches Ipratropium Bromide nasal spray in US

    Pharma major Lupin Ltd on Friday said it has launched Ipratropium Bromide nasal spray, used in treatment of runny nose, in the US market. The Ipratropium Bromide nasal solution (nasal…

    12 dead, 13 workers rescued as reactor blast rips through pharma unit near Hyderabad

    Bodies of 12 workers were brought out and 13 others were rescued from under the debris after a blast in a reactor unit at Sigachi Industries Pvt. Ltd. in the…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

    Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

    Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

    Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

    Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end